The stock has a 36-month beta value of 0.89. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for JAGX is 4.18M, and at present, short sellers hold a 7.49% of that float. On July 23, 2024, the average trading volume of JAGX was 799.52K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
JAGX) stock’s latest price update
Jaguar Health Inc (NASDAQ: JAGX)’s stock price has plunge by -64.88relation to previous closing price of 4.27. Nevertheless, the company has seen a -64.03% plunge in its stock price over the last five trading sessions. marketwatch.com reported 2024-07-23 that Jaguar Health Inc.’s stock JAGX, +0.23% tumbled 68% early Tuesday, after the biotech said a late-stage trial of a cancer drug failed to meet its main goal across all tumor types. San Francisco-based Jaguar said the Phase 3 trial of its crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy with or without standard chemotherapy did not meet its primary endpoint.
JAGX’s Market Performance
Jaguar Health Inc (JAGX) has seen a -64.03% fall in stock performance for the week, with a -61.74% decline in the past month and a -86.11% plunge in the past quarter. The volatility ratio for the week is 8.04%, and the volatility levels for the past 30 days are at 7.21% for JAGX. The simple moving average for the past 20 days is -61.48% for JAGX’s stock, with a -84.80% simple moving average for the past 200 days.
Analysts’ Opinion of JAGX
Many brokerage firms have already submitted their reports for JAGX stocks, with Cantor Fitzgerald repeating the rating for JAGX by listing it as a “Overweight.” The predicted price for JAGX in the upcoming period, according to Cantor Fitzgerald is $5 based on the research report published on July 07, 2021 of the previous year 2021.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see JAGX reach a price target of $2. The rating they have provided for JAGX stocks is “Buy” according to the report published on July 11th, 2017.
JAGX Trading at -75.25% from the 50-Day Moving Average
After a stumble in the market that brought JAGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -96.41% of loss for the given period.
Volatility was left at 7.21%, however, over the last 30 days, the volatility rate increased by 8.04%, as shares sank -60.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -91.87% lower at present.
During the last 5 trading sessions, JAGX fell by -63.79%, which changed the moving average for the period of 200-days by -89.51% in comparison to the 20-day moving average, which settled at $3.78. In addition, Jaguar Health Inc saw -83.49% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for JAGX
Current profitability levels for the company are sitting at:
- -3.18 for the present operating margin
- 0.67 for the gross margin
The net margin for Jaguar Health Inc stands at -3.78. The total capital return value is set at -0.86. Equity return is now at value -351.06, with -68.24 for asset returns.
Based on Jaguar Health Inc (JAGX), the company’s capital structure generated 0.69 points at debt to capital in total, while cash flow to debt ratio is standing at -0.93. The debt to equity ratio resting at 2.25. The interest coverage ratio of the stock is -6.71.
Currently, EBITDA for the company is -31.53 million with net debt to EBITDA at -0.73. When we switch over and look at the enterprise to sales, we see a ratio of 2.89. The receivables turnover for the company is 5.92for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.89.
Conclusion
To sum up, Jaguar Health Inc (JAGX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
